At the same time, some dual ICIs, such as AK-104 (anti-PD-1/CTLA-4 bispecific antibody), have been registered for clinical research on cervical cancer (NCT04380805; NCT05063916; NCT05235516; NCT04982237; NCT04868708). Here, CTLA4 is linked to cervical carcinoma.